GU Cancers 2024 | ARAMON: darolutamide versus enzalutamide monotherapy in CSPC

Whilst findings from the EMBARK trial (NCT02319837) have demonstrated the efficacy of enzalutamide in prostate cancer, darolutamide has been found to have a low blood–brain barrier (BBB) penetration, thus have lower neurological side effects. Andrew Laccetti, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the trial design of the Phase II ARAMON trial (NCT05526248) of darolutamide versus enzalutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence. The primary endpoint will be change in serum testosterone level at three months. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.